Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 INDICATION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PIPELINE ANALYSIS
4 REGULATORY FRAMEWORK OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET
5 EPIDEMIOLOGY
6 ADALIMUMAB PRESCRIPTION
7 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO
7.1 REIMBURSEMENT SCENARIO IN THE U.S.
7.2 REIMBURSEMENT SCENARIO IN CHINA
7.3 REIMBURSEMENT SCENARIO IN JAPAN
7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE
7.5 REIMBURSEMENT SCENARIO IN DENMARK
7.6 REIMBURSEMENT SCENARIO IN IRELAND
8 IMPACT OF BIOSIMILAR
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS
9.1.2 INCREASING GERIATRIC POPULATION
9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS
9.1.4 INTRODUCTION TO BIOSIMILARS
9.1.5 EXPLORATION OF EMERGING MARKETS
9.2 RESTRAINTS
9.2.1 HIGH COSTS OF DRUGS
9.2.2 SIDE EFFECTS OF DRUGS
9.2.3 CANCER CAUSING DRUGS
9.3 OPPORTUNITIES
9.3.1 PRESENCE OF PRODUCT PIPELINE
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 INCREASING HEALTHCARE EXPENDITURE
9.3.4 PRESENCE OF REIMBURSEMENT POLICIES
9.4 CHALLENGES
9.4.1 LOSS OF PATENTS
9.4.2 AVAILABILITY OF ALTERNATIVES
9.4.3 LONG APPROVAL PROCEDURE
10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY
10.1 OVERVIEW
10.2 ADALIMUMAB AND COVID-19
10.3 PRICE IMPACT OF COVID-19
10.4 IMPACT ON DEMAND
10.5 IMPACT ON SUPPLY CHAIN
10.6 STRATEGIC DECISIONS FOR MANUFACTURERS
10.7 CONCLUSION
11 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION
11.1 OVERVIEW
11.2 RHEUMATOID ARTHRITIS
11.3 ANKYLOSING SPONDYLITIS
11.4 CHRONIC PLAQUE PSORIASIS
11.5 CROHN’S DISEASE
11.6 ULCERATIVE COLITIS
11.7 PSORIATIC ARTHRITIS
11.8 JUVENILE IDIOPATHIC ARTHRITIS
11.9 HIDRADENITIS SUPPURATIVA
11.1 NON-INFECTIOUS INTERMEDIATE
11.11 OTHERS
12 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE
12.1 OVERVIEW
12.2 BIOLOGICS
12.3 BIOSIMILARS
12.3.1 ADALIMUMAB-ATTO
12.3.2 ADALIMUMAB-BWWD
12.3.3 ADALIMUMAB-ADBM
12.3.4 ADALIMUMAB-ADAZ
12.3.5 ADALIMUMAB-FKJP
12.3.6 ADALIMUMAB-AFZB
12.3.7 OTHERS
13 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH
13.1 OVERVIEW
13.2 MG/0.4ML
13.3 MG/0.8ML
13.4 MG/0.4ML
13.5 MG/0.1ML
13.6 OTHERS
14 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 BRANDED
14.3 GENERICS
14.3.1 AMJEVITA
14.3.2 HYRIMOZ
14.3.3 HULIO
14.3.4 OTHERS
15 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 PARENTERAL
15.3 ORAL
16 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE
16.1 OVERVIEW
16.2 ADULTS
16.3 CHILDREN
17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACIES
18.3 RETAIL PHARMACIES
18.4 ONLINE PHARMACIES
18.5 DIRECT TENDER
18.6 OTHERS
19 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY GEOGRAPHY
19.1 MIDDLE EAST & AFRICA
19.1.1 SAUDI ARABIA
19.1.2 SOUTH AFRICA
19.1.3 UAE
19.1.4 ISRAEL
19.1.5 KUWAIT
19.1.6 EGYPT
19.1.7 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
21 SWOT
22 COMPANY PROFILES
22.1 ABBVIE INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 BIOGEN
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 PRODUCT PORTFOLIO
22.3.4 RECENT DEVELOPMENTS
22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)}
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 PRODUCT PORTFOLIO
22.4.4 RECENT DEVELOPMENTS
22.5 MYLAN N.V.
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 CELLTRION INC.
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 COHERUS BIOSCIENCES
22.8.1 COMPANY SNAPSHOT
22.8.2 PRODUCT PORTFOLIO
22.8.3 RECENT DEVELOPMENTS
22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)
22.9.1 COMPANY SNAPSHOT
22.9.2 REVENUE ANALYSIS
22.9.3 PRODUCT PORTFOLIO
22.9.4 RECENT DEVELOPMENTS
22.1 HETERO BIOPHARMA LTD.
22.10.1 COMPANY SNAPSHOT
22.10.2 PRODUCT PORTFOLIO
22.10.3 RECENT DEVELOPMENTS
22.11 INNOVENT BIOLOGICS, INC.
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 PFIZER INC.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 ZYDUS CADILA
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENT
23 QUESTIONNAIRE
24 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, PIPELINE ANALYSIS
TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.
TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)
TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS
TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT
TABLE 6 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 58 SAUDI ARABIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 59 SAUDI ARABIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 60 SAUDI ARABIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 61 SAUDI ARABIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 62 SAUDI ARABIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 63 SAUDI ARABIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 64 SAUDI ARABIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 65 SAUDI ARABIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 66 SAUDI ARABIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 67 SAUDI ARABIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 68 SOUTH AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 69 SOUTH AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 70 SOUTH AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 SOUTH AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 72 SOUTH AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 73 SOUTH AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 74 SOUTH AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 75 SOUTH AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 76 SOUTH AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 77 SOUTH AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 78 UAE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 79 UAE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 UAE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 81 UAE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 82 UAE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 83 UAE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 84 UAE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 85 UAE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 86 UAE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 87 UAE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 88 ISRAEL ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 89 ISRAEL ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 90 ISRAEL BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 91 ISRAEL ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 92 ISRAEL ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 93 ISRAEL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 94 ISRAEL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 95 ISRAEL ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 96 ISRAEL ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 97 ISRAEL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 98 KUWAIT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 99 KUWAIT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 100 KUWAITBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 101 KUWAIT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 102 KUWAIT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 103 KUWAIT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 104 KUWAIT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 105 KUWAIT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 106 KUWAIT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 107 KUWAIT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 108 EGYPT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 109 EGYPT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 110 EGYPT BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 111 EGYPT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)
TABLE 112 EGYPT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 113 EGYPT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
TABLE 114 EGYPT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 115 EGYPT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)
TABLE 116 EGYPT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 117 EGYPT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 118 REST OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SEGMENTATION
FIGURE 11 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE MIDDLE EAST & AFRICA ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ADALIMUMAB MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET
FIGURE 14 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 15 FUNCTION OF CRO
FIGURE 16 HEALTHCARE EXPENDITURE IN 2016 AND 2019
FIGURE 17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, 2019
FIGURE 18 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION)
FIGURE 19 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027)
FIGURE 20 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 21 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE, 2019
FIGURE 22 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 24 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019
FIGURE 26 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027)
FIGURE 28 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE, 2019
FIGURE 30 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 32 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 33 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 34 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 35 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 36 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, 2019
FIGURE 38 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION)
FIGURE 39 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027)
FIGURE 40 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 41 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, 2019
FIGURE 42 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 43 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027)
FIGURE 44 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 46 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 47 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 48 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SNAPSHOT (2019)
FIGURE 50 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019)
FIGURE 51 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)
FIGURE 52 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)
FIGURE 53 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)
FIGURE 54 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)
